Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.
Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.
World Health Organization experts said it would be irresponsible for any scientist to conduct human gene-editing studies in people, and a central registry of research plans should be set up to ensure transparency,
People who consume lots of sugary sodas and sports drinks every day may be more likely to die early of causes like heart disease and cancer than people who rarely if ever indulge in these beverages, a U.S. study suggests.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
The U.S. Food and Drug Administration placed a partial clinical hold on all trials of AbbVie’s Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the cancer drug arm of the late-stage study.
A high dose of Amarin Corp.’s omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data.
Ohio’s attorney general filed a lawsuit against UnitedHealth Group Inc.’s OptumRx unit, saying the pharmacy benefit manager had overcharged the state nearly $16 million for prescription drugs.
The Apple Watch was able to detect irregular heart pulse rates that could signal the need for further monitoring for a serious heart rhythm problem, according to data from a large study funded by Apple Inc.
India’s health ministry called for Juul Labs Inc.’s electronic cigarettes to be blocked from entering the country, a letter seen by Reuters showed, potentially dealing a blow to the U.S. company’s plans to tap the South Asian market.